JP Morgan Chase (JPM) begins the new week with the possibility of new turmoil. Over the weekend The Wall Street Journal reported that CEO and Chairman Jamie Dimon has threatened to leave the company. That is, if shareholders vote split his duties. Dimon's dual role at the company has become the source of contention in the wake of the London Whale trading scandal. Ballots in a non-binding vote will be counted next week to split the chairman and CEO positions. Dimon reportedly spoke of leaving at a private meeting last week. JP Morgan stock is up 40% over the past year. It hit its high back in March.
Next up, San Francisco-based drug maker Theravance (THRX), which is currently up 12% in early trading. Theravance shot up more than 11% on Friday when the FDA approved a new drug it has been testing for C.O.P.D. Meantime, over the weekend, the Irish pharmaceutical company Elan struck a $1-billion deal with Theravance for royalties on that drug and 3-others in late-stage development. This is an intriguing deal because Elan has been fighting a takeover bid. But the company says the new deal with Theravance is totally independent of the other battle.
Now, another drug maker, Merrimack Pharmaceuticals (MACK), which reports today. This is a small cap company. Shares rose almost 6% on Friday. Merrimack is focused on developing treatments for cancer. Last month the company reported that a lung cancer drug failed in phase-2 trials. Shares dropped steeply at that point. They've climbed back a bit but are still down 19% this year. The company is expected to post losses of 28-cents a share, but that's a vast improvement from last year when they were more than $2 a share.
Finally this morning, a company that may have played a part in your breakfast: Post Holdings (POST), which was up 3 1/4 percent on Friday. The company is set to report earnings after today's closing bell. You may recall it was spun off from Ralcorp at the beginning of 2012. Just last week it announced the purchase of Hearthside which is a cereal, granola and snack company. Post is expected to post 27-cents a share, down more than 25% with a rise in revenue on higher costs. The stock is up 74% since its debut and it now at an all-time high.
- Health Care Industry
- Jamie Dimon